• BridgeBio priced up to USD 1 billion in newly issued Series A Cumulative Convertible Participating Preferred Stock in a private placement.
• Sixth Street funded USD 800 million; HealthCare Royalty, a KKR business, funded USD 133.9 million at the initial close.
• Preferred carries a 7% initial dividend, payable in kind or cash at BridgeBio’s election.
• Initial conversion price set at USD 137.79 per share; steps up to USD 153.1 from the fifth anniversary.
• Security structured as permanent equity with no scheduled maturity; BridgeBio holds cash redemption or forced conversion rights in defined cases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-027445), on July 02, 2026, and is solely responsible for the information contained therein.